Peringatan Keamanan

Case reports involving pheniramine overdosage mention the rare possibility of arrythmias, cutaneous eruptions, and rhabdomyolysis with acute kidney injury.A181676,A181679,A181682 The administration of activated charcoal effectively prevents the absorption of pheniramine as it largely adsorbs to the charcoal, therefore this may be of benefit in cases of overdose if provided early after ingestion.A181685

Pheniramine

DB01620

small molecule approved

Deskripsi

Pheniramine is a first-generation antihistamine in the alkylamine class, similar to brompheniramine and chlorpheniramine.A181628 It is used in
some over-the-counter allergy as well as cold & flu products in combination with other drugs. Pheniramine's use as an anti-allergy medication has largely been supplanted by second-generation antihistamines such as cetirizine and loratadine.

Struktur Molekul 2D

Berat 240.3434
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal half-life of pheniramine administered via IV is 8-17 h.[A181640]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

The administration of 30.5 mg of free base pheniramine resulted in a Cmax of 173-294 ng/mL with a Tmax of 1-2.5 h.A181640

Metabolisme

Pheniramine undergoes N-dealkylation to N-didesmethylpheniramine and N-desmethylpheniramine.A181628

Rute Eliminasi

Pheniramine is eliminated by metabolism and via renal excretion.A181628 24.3% of pheniramine is present in the urine as the parent drug.

Interaksi Obat

401 Data
Benzylpenicilloyl polylysine Pheniramine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Pheniramine.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Pheniramine.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Pheniramine.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.
Amphetamine Amphetamine may decrease the sedative activities of Pheniramine.
Phentermine Phentermine may decrease the sedative activities of Pheniramine.
Benzphetamine Benzphetamine may decrease the sedative activities of Pheniramine.
Diethylpropion Diethylpropion may decrease the sedative activities of Pheniramine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Pheniramine.
Mephentermine Mephentermine may decrease the sedative activities of Pheniramine.
MMDA MMDA may decrease the sedative activities of Pheniramine.
Midomafetamine Midomafetamine may decrease the sedative activities of Pheniramine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Pheniramine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Pheniramine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Pheniramine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Pheniramine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Pheniramine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Pheniramine.
Metamfetamine Metamfetamine may decrease the sedative activities of Pheniramine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Pheniramine.
Ritobegron Ritobegron may decrease the sedative activities of Pheniramine.
Mephedrone Mephedrone may decrease the sedative activities of Pheniramine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Pheniramine.
Gepefrine Gepefrine may decrease the sedative activities of Pheniramine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Pheniramine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Pheniramine.
Leuprolide The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sulfisoxazole.
Amitriptyline The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Amitriptyline.
Methadone The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Diltiazem.
Clozapine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nimodipine.
Promazine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Prochlorperazine.
Droperidol The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Droperidol.
Imipramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Imipramine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chlorpromazine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pheniramine.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Atropine.
Chloroquine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Papaverine.
Nifedipine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ofloxacin.
Propafenone The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Propafenone.
Flecainide The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Flecainide.
Clarithromycin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clarithromycin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levacetylmethadol.
Saquinavir The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Saquinavir.
Clomipramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clomipramine.
Mibefradil The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Probucol.
Aceprometazine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Aceprometazine.
Terlipressin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Terlipressin.
Prenylamine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Telavancin.
Pazopanib The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pazopanib.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nemonoxacin.
Panobinostat The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Panobinostat.
Nilvadipine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nilvadipine.

Target Protein

Histamine H4 receptor HRH4
Histamine H1 receptor HRH1
Nuclear receptor subfamily 1 group I member 3 NR1I3

Referensi & Sumber

Artikel (PubMed)
  • PMID: 9795048
    Schulze FR, Buschauer A, Schunack W: Combined histamine H1/H2 receptor antagonists: part I. Pharmacological hybrids with pheniramine- and roxatidine-like substructures. Eur J Pharm Sci. 1998 Jul;6(3):177-86.
  • PMID: 22918191
    Wade L, Bielory L, Rudner S: Ophthalmic antihistamines and H1-H4 receptors. Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):510-6. doi: 10.1097/ACI.0b013e328357d3ba.
  • PMID: 4385103
    Kabasakalian P, Taggart M, Townley E: Urinary excretion of pheniramine and its N-demthylated metabolites in man--comparison with chlorpheniramine and brompheniramine data. J Pharm Sci. 1968 Apr;57(4):621-3. doi: 10.1002/jps.2600570416.
  • PMID: 3988394
    Witte PU, Irmisch R, Hajdu P: Pharmacokinetics of pheniramine (Avil) and metabolites in healthy subjects after oral and intravenous administration. Int J Clin Pharmacol Ther Toxicol. 1985 Jan;23(1):59-62.
  • PMID: 25948974
    Venugopal K, Reddy MM, Bharathraj MY, Jaligidad K, Kushal DP: Pheniramine Maleate-Induced Rhabdomyolysis and Aki: Is it Fatal? Toxicol Int. 2014 Sep-Dec;21(3):319-21. doi: 10.4103/0971-6580.155384.
  • PMID: 1065303
    Bobik A, McLean AJ: Cardiovascular complications due to pheniramine overdosage. Aust N Z J Med. 1976 Feb;6(1):65-7.
  • PMID: 30142724
    Gupta A, Arora P, Malhotra P, Sardana K: Pheniramine maleate: an apparently safe drug causing bullous fixed drug eruption. Dermatol Online J. 2018 Aug 23;24(6).
  • PMID: 679637
    Boehm JJ, Brown TC, Oppenheim RC: Reduction of pheniramine toxicity using activated charcoal. Clin Toxicol. 1978;12(5):523-30. doi: 10.3109/15563657809150026.
Textbook
  • ISBN: 978-1-25-958473-2
    Brunton LL, Hilal-Dandan R, Knollmann BC. eds (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.

Contoh Produk & Brand

Produk: 159 • International brands: 1
Produk
  • Alahist D
    Tablet • - • Oral • US • OTC
  • Alahist DM
    Liquid • - • Oral • US • OTC
  • Allergy Eye Drops
    Solution / drops • - • Ophthalmic • US • Generic • OTC • Approved
  • Allergy Eye Drops
    Solution / drops • - • Ophthalmic • US • Generic • OTC • Approved
  • Allergy Eye Drops
    Solution / drops • - • Ophthalmic • Canada • OTC • Approved
  • Antitussive Decong Antihistamine Syr
    Syrup • - • Oral • Canada • OTC • Approved
  • Bronchodex D Cap
    Capsule, extended release • - • Oral • Canada • OTC • Approved
  • Bronchodex Pediatrique
    Syrup • - • Oral • Canada • OTC • Approved
Menampilkan 8 dari 159 produk.
International Brands
  • AVIL

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul